1. 17th Expert Committee on the Selection and Use of Essential Medicines. Review of the available evidence on Lamotrigine for epilepsy for the WHO model list of essential medicines. Geneva, March 2009. Available from URL: http://www.who.int/selection_medicines/committees/expert/17/application/lamotrigine_inclusion.pdf . Accessed on 6 January, 2010.
2. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al.; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015.
3. Zubcevic S, Cengic A, Catibusic F, Uzicanin S. Use of lamotrigine in medically intractable epilepsies in children. Med Arh. 2008;62:162–164.
4. Chen SJ, Chang KP, Wong TT, Kwan SY, Hsu ML, Wang CC. Lamotrigine adjunctive therapy in children with refractory epilepsy: a medical center study. Acta Paediatr Taiwan. 2006; 47:123–126.
5. Vigneswari G, Sofiah A, Hussain IH. Lamotrigine as an add-on therapy in intractable paediatric epilepsy — the Kuala Lumpur Hospital experience. Med J Malaysia. 2001;56:359–364.